Table 2 League table comparing the effects of treatments for primary outcomes.

From: Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

FPG (mmol/L)

Tir

−1.10

(−1.83, −0.37)

−1.50

(−2.28, −0.73)

−1.58

(−2.29, −0.86)

−1.69

(−2.61, −0.77)

 

−2.19

(−3.04, −1.34)

−1.79

(−2.53, −1.06)

−2.75

(−3.58, −1.92)

−3.07

(−3.75, −2.39)

−0.80

(−1.19, −0.40)

Sem

−0.41

(−0.95, 0.14)

−0.48

(−1.01, 0.05)

−0.59

(−1.28, 0.10)

 

−1.09

(−1.77, −0.41)

−0.70

(−1.19, −0.21)

−1.65

(−2.32, −0.99)

−1.97

(−2.45, −1.49)

−1.12

(−1.50, −0.74)

−0.32

(−0.51, −0.13)

Lir

−0.07

(−0.58, 0.44)

−0.18

(−0.85, 0.48)

 

−0.68

(−1.37, −0.00)

−0.29

(−0.69, 0.12)

−1.25

(−1.92, −0.58)

−1.57

(−2.08, −1.05)

−1.18

(−1.55, −0.81)

−0.38

(−0.57, −0.20)

−0.06

(−0.22, 0.10)

Dul

−0.11

(−0.83, 0.61)

 

−0.61

(−1.29, 0.06)

−0.22

(−0.63, 0.20)

−1.17

(−1.83, −0.51)

−1.49

(−1.99, −1.00)

−1.17

(−1.59, −0.74)

−0.37

(−0.62, −0.12)

−0.05

(−0.28, 0.19)

0.01

(−0.24, 0.26)

EQW

 

−0.50

(−1.35, 0.34)

−0.11

(−0.73, 0.52)

−1.06

(−1.90, −0.23)

−1.38

(−2.11, −0.66)

−1.40

(−1.90, −0.91)

−0.60

(−0.97, −0.24)

−0.28

(−0.61, 0.05)

−0.22

(−0.57, 0.13)

−0.23

(−0.62, 0.16)

Alb

    

−1.47

(−1.89, −1.05)

−0.68

(−0.95, −0.40)

−0.35

(−0.60, −0.10)

−0.29

(−0.55, −0.04)

−0.31

(−0.62, 0.00)

−0.07

(−0.47, 0.33)

EBID

−0.40

(−1.01, 0.22)

−0.56

(−1.22, 0.10)

−0.88

(−1.44, −0.33)

−1.52

(−1.90, −1.15)

−0.73

(−0.91, −0.55)

−0.40

(−0.54, −0.27)

−0.34

(−0.48, −0.20)

−0.36

(−0.59, −0.13)

−0.12

(−0.45, 0.21)

−0.05

(−0.29, 0.19)

Oth

−0.96

(−1.57, −0.35)

−1.28

(−1.75, −0.81)

−1.76

(−2.16, −1.35)

−0.96

(−1.21, −0.71)

−0.63

(−0.86, −0.41)

−0.57

(−0.81, −0.34)

−0.59

(−0.88, −0.30)

−0.35

(−0.74, 0.03)

−0.28

(−0.53, −0.03)

−0.23

(−0.45, −0.01)

Lix

−0.32

(−0.83, 0.19)

−2.33

(−2.69, −1.96)

−1.53

(−1.72, −1.34)

−1.20

(−1.36, −1.05)

−1.14

(−1.31, −0.97)

−1.16

(−1.40, −0.92)

−0.92

(−1.28, −0.57)

−0.85

(−1.06, −0.64)

−0.80

(−0.96, −0.64)

−0.57

(−0.75, −0.39)

Pla

HbA1-c (%)

  1. The top half of the table represents pair-to-pair comparisons for FPG (mmol/L); the bottom half represents pair-to-pair comparisons for HbA1-c (%).
  2. Alb: Albiglutide; Dul: Dulaglutide; EBID: Twice-daily exenatide; EQW: Once-weekly exenatide; Lir: Liraglutide; Lix: Lixisenatide; Sem: Semaglutide; Tir: Tirzepatide; Pla: Placebo; Oth: Traditional antidiabetic drugs (insulin, metformin, sulfonylureas, DDP-4 is and SGLT-2 is).
Back to article page